Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P00751
UPID:
CFAB_HUMAN
Alternative names:
C3/C5 convertase; Glycine-rich beta glycoprotein; PBF2; Properdin factor B
Alternative UPACC:
P00751; B0QZQ6; O15006; Q29944; Q53F89; Q5JP67; Q5ST50; Q96HX6; Q9BTF5; Q9BX92
Background:
Complement factor B, also known as C3/C5 convertase, plays a crucial role in the alternative pathway of the complement system. It is cleaved into two fragments, Ba and Bb, with Bb acting as a serine protease that combines with complement factor 3b to generate the C3 or C5 convertase. This protein is also involved in the proliferation and differentiation of preactivated B-lymphocytes, among other immune responses.
Therapeutic significance:
Complement factor B is implicated in several diseases, including age-related macular degeneration, atypical hemolytic uremic syndrome, and complement factor B deficiency. These associations highlight its potential as a target for therapeutic intervention in conditions related to the immune system and beyond.